Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RLMD	$3.83	+0.52%	1.31M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RLMD	$3.83	+0.5%	1.31M
3
4
5
6

RLMD

Get Relmada Therapeutics, Inc. Data in Excel

Get Relmada Therapeutics, Inc. Data in Excel